OBJECTIVE: The present study was designed to test whether transplantation of human bone marrow-derived mesenchymal stem cells (hMSCs) in New Zealand rabbits with myocardial infarction can improve heart function; and whether engrafted donor cells can survive and transdifferentiated into cardiomyocytes. METHODS: Twenty milliliters bone marrow was obtained from healthy men by bone biopsy. A gradient centrifugation method was used to separate bone marrow cells (BMCs) and red blood cells. BMCs were incubated for 48 h and then washed with phosphate-buffered saline (PBS). The culture medium was changed twice a week for 28 d. Finally, hematopoietic cells were washed away to leave only MSCs. Human MSCs (hMSCs) were premarked by BrdU 72 h before the transplantation. Thirty-four New Zealand rabbits were randomly divided into myocardial infarction (MI) control group and cell treated group, which received hMSCs (MI+MSCs) through intramyocardial injection, while the control group received the same volume of PBS. Myocardial infarction was induced by ligation of the left coronary artery. Cell treated rabbits were treated with 5 x 10(6) MSCs transplanted into the infarcted region after ligation of the coronary artery for 1 h, and the control group received the same volume of PBS. Cyclosporin A (oral solution; 10 mg/kg) was provided alone, 24 h before surgery and once a day after MI for 4 weeks. Echocardiography was measured in each group before the surgery and 4 weeks after the surgery to test heart function change. The hearts were harvested for HE staining and immunohistochemical studies after MI and cell transplantation for 4 weeks. RESULTS: Our data showed that cardiac function was significantly improved by hMSC transplantation in rabbit infarcted hearts 4 weeks after MI (ejection fraction: 0.695+/-0.038 in the cell treated group (n=12) versus 0.554+/-0.065 in the control group (n=13) (P<0.05). Surviving hMSCs were identified by BrdU positive spots in infarcted region and transdifferentiated into cardiomyocytes characterized with a positive cardiac phenotype: troponin I. CONCLUSION: Transplantation of hMSCs could transdifferentiate into cardiomyocytes and regenerate vascular structures, contributing to functional improvement.
OBJECTIVE: The present study was designed to test whether transplantation of human bone marrow-derived mesenchymal stem cells (hMSCs) in New Zealand rabbits with myocardial infarction can improve heart function; and whether engrafted donor cells can survive and transdifferentiated into cardiomyocytes. METHODS: Twenty milliliters bone marrow was obtained from healthy men by bone biopsy. A gradient centrifugation method was used to separate bone marrow cells (BMCs) and red blood cells. BMCs were incubated for 48 h and then washed with phosphate-buffered saline (PBS). The culture medium was changed twice a week for 28 d. Finally, hematopoietic cells were washed away to leave only MSCs. Human MSCs (hMSCs) were premarked by BrdU 72 h before the transplantation. Thirty-four New Zealand rabbits were randomly divided into myocardial infarction (MI) control group and cell treated group, which received hMSCs (MI+MSCs) through intramyocardial injection, while the control group received the same volume of PBS. Myocardial infarction was induced by ligation of the left coronary artery. Cell treated rabbits were treated with 5 x 10(6) MSCs transplanted into the infarcted region after ligation of the coronary artery for 1 h, and the control group received the same volume of PBS. Cyclosporin A (oral solution; 10 mg/kg) was provided alone, 24 h before surgery and once a day after MI for 4 weeks. Echocardiography was measured in each group before the surgery and 4 weeks after the surgery to test heart function change. The hearts were harvested for HE staining and immunohistochemical studies after MI and cell transplantation for 4 weeks. RESULTS: Our data showed that cardiac function was significantly improved by hMSC transplantation in rabbitinfarcted hearts 4 weeks after MI (ejection fraction: 0.695+/-0.038 in the cell treated group (n=12) versus 0.554+/-0.065 in the control group (n=13) (P<0.05). Surviving hMSCs were identified by BrdU positive spots in infarcted region and transdifferentiated into cardiomyocytes characterized with a positive cardiac phenotype: troponin I. CONCLUSION: Transplantation of hMSCs could transdifferentiate into cardiomyocytes and regenerate vascular structures, contributing to functional improvement.
Authors: M Scorsin; F Marotte; A Sabri; O Le Dref; M Demirag; J L Samuel; L Rappaport; P Menasché Journal: Circulation Date: 1996-11-01 Impact factor: 29.690
Authors: R K Li; D A Mickle; R D Weisel; M K Mohabeer; J Zhang; V Rao; G Li; F Merante; Z Q Jia Journal: Circulation Date: 1997-11-04 Impact factor: 29.690
Authors: S Makino; K Fukuda; S Miyoshi; F Konishi; H Kodama; J Pan; M Sano; T Takahashi; S Hori; H Abe; J Hata; A Umezawa; S Ogawa Journal: J Clin Invest Date: 1999-03 Impact factor: 14.808
Authors: T Asahara; T Murohara; A Sullivan; M Silver; R van der Zee; T Li; B Witzenbichler; G Schatteman; J M Isner Journal: Science Date: 1997-02-14 Impact factor: 47.728
Authors: D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus Journal: Nat Med Date: 1998-08 Impact factor: 53.440
Authors: Sherif M Amr; Ashraf Gouda; Wael T Koptan; Ahmad A Galal; Dina Sabry Abdel-Fattah; Laila A Rashed; Hazem M Atta; Mohammad T Abdel-Aziz Journal: J Spinal Cord Med Date: 2013-11-26 Impact factor: 1.985
Authors: Hania Ibrahim Ammar; Glen Lester Sequiera; Mira B Nashed; Rasha I Ammar; Hala M Gabr; Hany E Elsayed; Niketa Sareen; Ejlal Abu-El Rub; Maha B Zickri; Sanjiv Dhingra Journal: Stem Cell Res Ther Date: 2015-08-22 Impact factor: 6.832